Warfarin, aspirin ve plasebonun karsilastirildigi AFASAK, SPAF I, BAATAF
, SPINAF, EAFT, SPAF II calismalarinda, warfarin ve aspirin tedavilerinin her birinin plaseboya gore strok riskini anlamli azalttigi, warfarinin ise aspirin ile karsilastirildiginda cok daha iyi sonuclar verdigini gostermistir (1).
Five randomized, primary stroke prevention trials in patients with AF (Veteran Affairs SPAF, (4) BAATAF
, (5) AFASAK, (6) CAFA, (7) and SPINAF (8)) used their own risk stratification schemes.
In the BAATAF
study of low-dose warfarin, there was no difference in patient wellbeing or health perception between warfarin and placebo treatment groups although not surprisingly patients who had complications of warfarin therapy had a significant reduction in health perception.